I&EHL: EU Pharmaceutical Law André den Exter

Slides:



Advertisements
Similar presentations
6th European Patients’ Rights Day The EMA Geriatric Medicines Strategy and the empowered aging patient Francesca Cerreta EMA (European Medicines Agency)
Advertisements

Registration in Europe Current situation and future outlook Thomas K ü rner, M.D. Nippon Boehringer Ingelheim Co., Ltd.
World Health Organization
BACKGROUND: The Directorate General of Drug Administration under the Ministry of Health & Family Welfare, Government of the People's Republic of Bangladesh,
Medsafe – GMP update / release for supply / communicating quality issues Derek Fitzgerald Manager, Compliance Management 11 July 2013 RACI Pharmaceutical.
The Paediatric Regulation
André den Exter The EU-Ukraine Association Agreement and its Relevance to Health Care André den Exter
EU Cross-Border Care Directive from the Primary Care perspective Results of a simulation Rita Baeten Gothenburg, 3 September 2012.
FEDERAL AGENCY FOR MEDICINES AND HEALTH PRODUCTS Federal Agency for Medicines and Health Products (FAMHP) Compassionate Use and Medical Need Program Pharma.be-BeApp,
WHO Good Governance for Medicines programme Technical Briefing Seminar 19 November 2009, Geneva Dr Guitelle Baghdadi-Sabeti Department of Essential Medicines.
Title, date Mr. Einar Magnússon Director, Department of Pharmaceutical Affairs Ministry for Health.
Implementation - Medical Devices. Overview Act on Medical Devices – background and overview. Surveillance - Competent authority. Directive 93/42. Directive.
Advertising of rx medicinal products to the general public The case MSD Sharpe & Dohme GmbH vs. Merckle GmbH (C-316/09) Judgment of the ECJ of 5 May 2011.
FEDERAL REGULATIONS OF MEDICATIONS Food, Drug and Cosmetic Act Protect consumers from adulterated and misbranded foods, drugs, cosmetics, or devices.
EU System for Marketing Authorisation
Regulation of Pharmaceuticals in Kenya
1 FDA Thailand By HIV Module/Marketing Group Mr. Manaswee Arayasiri.
An introduction to the EU and its legislation. Member States currently 15 –Austria- Ireland –Belgium- Luxembourg –Denmark- Netherlands –Finland- Portugal.
Product Safety and Market Surveillance Package
3rd Baltic Conference on Medicines Economic Evaluation, Reimbursement and Rational Use of Pharmaceuticals Pricing and Reimbursement of Pharmaceuticals.
Requirements of EU pharmacovigilance legislation for distributors Julia Sipos Quality Management Director Pharmacovigilance coordinator Version 03.
Regulatory Update Ellen Leinfuss SVP, Life Sciences.
Eureka Pre-Clinical Investigation Animal toxicology Animal pharmacokinetics/ pharmacodynamics Clinical Investigation Phase I Safety and pharmacology Phase.
Conference: Generic Drugs in Turkey and the EU THE PORTUGUESE MODEL FOR STIMULATING GENERIC COMPETITION IN THE EU June 2, 2005, Ankara, Turkey Rui Santos.
European Commission Dialogue-Innovation-Future An experience of the Pharmaceutical Forum Dr Stefaan Van der Spiegel, MD Competitiveness in the Pharmaceuticals.
Data protection and extension of patent rights TRIPS requirements & TRIPS-plus provisions Carlos Correa.
Revision of the Medical Device Directives The case of ‘Borderline’ Products used in a self-care context 48th AESGP Annual Meeting Nice, 6-8 June 2012 Laurent.
1 Investing in Innovation Should the EU do more to match US investment in innovative medicines? Brian Ager EFPIA Gastein, 6 October 2004.
Clinical Trial Review and Approval: New Regulations and their implications Siddika Mithani, Ph.D Clinical Trials & Special Access Programme Therapeutic.
Authorisation of medicinal products: selected challenges Rocío Salvador Roldán Pharmaceuticals Unit/DG SANCO This presentation only reflects the views.
And Pharmaceuticals Health Technology Technical Cooperation for Essential Drugs and Traditional Medicine Challenges of Medicine Regulation in Africa Global.
SALDA Presentation to the Honourable Portfolio Committee on Health National Health Act Amendment Bill B March 2012.
1 10 th Annual European Scientific and Regulatory Affairs Conference New Pharmaceutical legislation: One year experience… 21 November 2006 Bernard Lemoine.
ACCESS TO MEDICINES - POLICY AND ISSUES
Review of veterinary medicines legislation in 2010 Mario Nagtzaam Unit F2 „Pharmaceuticals“ Directorate-General Enterprise and Industry European Commission.
WHO-Technical Briefing Seminar | October-November 2012 Dr Cécile Macé 1 |1 | Good Governance for Medicines Programme Dr Cécile Macé EMP/MPC.
Directorate General for Enterprise and Industry European Commission The New Legislative Framework - Market Surveillance UNECE “MARS” Group meeting Bratislava,
UPCOMING CHANGES TO IN-VITRO DIAGNOSTICS (IVDs) AND LABORATORY DEVELOPED TESTS (LDTs) REGULATIONS Moj Eram, PhD November 5, 2015.
Draft Law of Kyrgyz Republic on Medicinal Products Syrdybaev Suyunbek, Head of expert group of ISWG of MoH KR 4 th Forum of МеТА Kyrgyz Republic Bishkek,
European Patients’ Academy on Therapeutic Innovation Marketing authorisation.
Bangkok A Strong Generic Competition for a Sustainable Agriculture and an Innovative Dominant Industry.
TAIEX Workshop on the Implementation of EU Pharmacovigilance Legislation - BELGRADE CLAUDIA PANAIT TAIEX Expert – European Commission Legal Adviser.
China EU Pharmaceutical Forum
TAIEX GPSD Free Movement and Safety Vitomir Fister Beograd,
CLAUDIA PANAIT TAIEX Expert – European Commission Legal Adviser Ministry of Health, ROMANIA.
Date Insert on Master Slide Slide 1 Regulatory Framework within which patients can have safe and more convenient access to medicines Royal College of Physicians.
THE OFFICE FOR REGISTRATION OF MEDICINAL PRODUCTS, MEDICAL DEVICES AND BIOCIDAL PRODUCTS Responsibility in the handling of medical devices.
1 From Regulatory Intelligence to Compliance Debbie Henderson Head, Global Regulatory Policy EU Ring May 13, 2014.
M O N T E N E G R O Negotiating Team for the Accession of Montenegro to the European Union Working Group for Chapter 1 – Free movement of goods Bilateral.
M O N T E N E G R O Negotiating Team for the Accession of Montenegro to the European Union Working Group for Chapter 20 – Enterprise and Industrial policy.
M O N T E N E G R O Negotiating Team for the Accession of Montenegro to the European Union Working Group for Chapter 1 – Free movement of goods Bilateral.
Slide 1 The contribution of a world-class regulatory environment to the future of the industry in Ireland Pat O’Mahony Chief Executive, Irish Medicines.
M O N T E N E G R O Negotiating Team for the Accession of Montenegro to the European Union Working Group for Chapter 1 – Free movement of goods Bilateral.
Date: in 12 pts MARKET SURVEILLANCE IN THE EU ROLE IN THE NLF - EU ACTIONS and DEVELOPMENTS Rita L'Abbate European Commission DG ENTERPRISE AND INDUSTRY.
Off-label Use.
POST APPROVAL CHANGE MANAGEMENT PROTOCOLS IN THE EUROPEAN UNION
Update on EU regulatory developments
A capacity building programme for patient representatives
Periodic Safety Update Reports (PSUR)
Information on Medicinal Products
REGULATORY PROBLEMS IN CARING OUT PRE- AND POST- AUTHORISATION CLINICAL TRIALS Dr Penka Decheva GCP Inspector, BDA.
Dr Samvel Azatyan Technical Officer Regulatory Support
Multinational collaboration in the Authorisation of VMPs: the EU approach VICH Outreach Forum Tokyo, Nov 2017 Noel Joseph European Commission.
The role of the HPRA in the authorisation of veterinary medicinal products The role of the Health Products Regulatory Authority in the authorisation of.
PharmDr. Ján Mazag, director, State Institute for Drug Control
Commission strategy to
Dr Manisha Shridhar Regional Advisor WHO-SEARO
Prescription-only vs. over-the-counter medicines
P O S S I B L E F U T U R E N A T I O N A L L E G I S L A T I O N
Interconnection of good practices: from development to distribution
Presentation transcript:

I&EHL: EU Pharmaceutical Law André den Exter

1 Outline History Legal framework: Pharmaceutical chain Latest developments

2 History -Thalidomide drama -Pharmaceutical strategy (Directive 65/65/EEC) -Divergence in interests between different stakeholders

3 EU Pharmaceutical Policy: Regulating the pharmaceutical chain -From R&D towards using medicines: R&D, clinical trials, patents, registration, distribution, wholesale, packaging and labelling, pricing, retail, advertising, and privacy)

4 Legal Framework Public Health, Art 168 TFEU (4): (c) measures setting high standards of quality and safety for medicinal products and devices for medical use. Pharmaceutical law (pharma chain) Internal market and competition rules

5 What’s a medicine?

6 What is a medical product? Directive 2001/83/EC Art. 1: presentation or function CJEU case law: case-by-case approach - Borderline products - Differences in classification Relevance

7 Research & Development: Clinical Trials CTDirective 2001/20/EC Protection of clinical trial subjects Ethics Committee: pre-trial approval Notification adverse effects Good clinical practices

8 Manufacturing: Directive 2001/83/EC Basic requirements manufacturing: -Manufacturing authorization MS -Labelling and package leaflet -Classification -Advertising and information -Pharmacovigilance

9 Marketing Authorization Directive 2001/83/EC Regulation 726/2004/EC -Art. 6: MA required to place a medicinal product on the market, UNLESS… Compassianate use supply Pharmacy exemption (“Magistral formula”) Renewal of MA (art 24) Refusal of MA (art 26)

10 MA procedures National Procedure: -Application to national competent authority -Procedures governed by national law -Transparency -First step towards MR procedure Mutual Recognition/Decentralised Procedure -Application to reference member state (RMS) -Grounds for refusing to recognise RMS approval -EMA Commission referral for arbitration Centralised Procedure -Scope: high-technology medicinal products -Application to EMA: Eur. Cie.

11 Specific procedures Orphan Drug Products (Reg. No 141/2000 (ODR) -Purpose -Community marketing authorisation -Market exclusivity (art 8) -‘breaking’ market exclusivity -Criticism ODR Medicinal products for paediatric use( Reg.1901/2006) -Purpose -Paediatric population -Paediatric Committee -Marketing Authorization requirements

12 Information and Advertising (ART ) Complete harmonization Classification of products General/specific conditions advertising Latest regulatory proposal: information to patients

13 Inducement: GSK vioxx training course at Arabella Golf Resort Mallorca

14 Retail sale: Pharmacies -No harmonized rules (except for labelling/ leaflets and advertising) -Only rules on classification -Ownership, free movement, and public health exception -Infringement proceedings

15 Pricing Directive (89/105/EEC) -Transparency pricing measures: Directly controlled price Use of international price comparisons: maximum price Profit controls Not harmonised: Reimbursement -Assessment of therapeutic benefits/clinical relevance, cost-effectiveness and outcomes -Positive and negative lists -Reference price systems -Co-payments, substitution and bonus system

16 Pharmacovigilance What is pharmacovigilance? Legal requirements pre- and post authorization phases: -2001/83/EC and 726/2004/EU: Establishing pharmacovig. system MS (art 102) Qualified person and systems (art. 103) Reporting of Adverse reactions -Spontaneous reporting -Periodical reports all adverse reactions 104(6) -Eudravigilance system Pharmacovig. inspections (art. 111) EMA’s role in pharmacovigilance Supervision and sanctions (art 116 )

17 Latest developments Legislative proposals: -Tackle counterfeit medicines (Dir 2011/64/EU) -Information prescription-only medicines -Pharmacovigilance 2012 amendments Outsourcing/offshoring CTs in developing countries Seizures of In-Transit Medicines